冠状动脉慢血流现象治疗的研究进展

Abstract
Figure/Table
References (41)
Related Citation (15)

Download: PDF (534 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Clinical for repeated chest pain coronary angiography found in some patients with coronary artery and no clear stenosis, but its distal blood flow is delayed perfusion, except after thrombolysis, coronary plasty, coronary spasm,coronary expansion, cardiomyopathy, valve disease and a series of diseases, this phenomenon will be called coronary artery slow flow phenomenon.Coronary slow blood flow shows recurrent resting angina and may lead to serious cardiovascular events such as acute myocardial infarction, fatal arrhythmia and sudden cardiac death, and reduce the quality of life and life of patients.In recent years, due to the continuous development of coronary intervention technology, the phenomenon of coronary slow flow has gradually been paid attention to, but people still have little understanding of its pathogenesis and treatment, and a clear understanding of the treatment and prognosis of coronary slow flow phenomenon is lacking.This paper focuses on slow flow phenomenon of normal or near normal coronary artery, and summarize the possible pathogenesis, treatment, and the prognostic impact of the disease, and make a brief review of the research progress and treatment of slow blood flow phenomena in coronary arteries.

Key words： Coronary slow flow phenomenon Harm Treatment Research progress.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I23/30

[1]	He W，Huang Y，Zhang Y，et al.Cardiac rehabilitation therapy for coronary slow flow phenomenon[J].Herz，2020，45（5）：468-474.
[2]	李冬梅，孟庆鑫，李忠娟，等.24 小时动态心电图在冠状动脉慢血流中的应用分析[J].中国医药科学，2021，11（11）：198-200，215.
[3]	Knuuti J，Wijns W，Saraste A，et al.2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J].Eur Heart J，2020，41（3）：4242.
[4]	Gibson CM，Cannon CP，Daley WL，et al.TIMI frame count：A quantitative method of assessing coronary artery flow[J].Circulation，1996，93（5）：879-888.
[5]	Nie SP，Wang X，Geng LL，et al.Anatomic properties of coronary arteries are correlated to the corrected thrombolysis in myocardial infarction frame count in the c oronary slow flow phenomenon[J].Coron Artery Dis，2012，23（3）：174-180.
[6]	Hawkins BM，Stavrakis S，Rousan TA，et al.Coronary slow flow-prevalence and clinical correlations[J].Circ J，2012，76（4）：936-942.
[7]	Leone MC，Gori T，Fineschi M.The coronary slow flow phenomenon：A new cardiac "Y" syndrome?[J].Clin Hemorheol Microcirc，2008，39（1-4）：185-190.
[8]	Naing Z，Qiu CG.Dawn of the most influential mechanism from the nightmare of slow coronary flow phenomenon：A randomized controlled study[J].Int J Cardiol，2013，168（5）：4951-4953.
[9]	Chalikias G，Tziakas D.Slow coronary flow：Pathophysiology，clinical implications，and therapeutic management[J].Angiology，2021，72（9）：808-818.
[10]	Mehta HH，Morris M，Fischman DL，et al.The spontaneous coronary slow-flow phenomenon：Reversal by Intracoronary Nicardipine[J].J Invasive Cardiol，2019，31（3）：42-45.
[11]	陈韵岱，王长华.急性心肌梗死经皮冠状动脉介入治疗术后无复流的防治进展[J].中国循环杂志，2010，25（3）：165-166.
[12]	隋春兴，王超，孙世泽，等.冠脉内注射法舒地尔预防急性心肌梗死原发经皮介入治疗中慢血流及无复流的效果[J].中国老年学杂志，2015，35（4）：960-962.
[13]	Myers PR，Banitt PF，Guerra R，et al.Characteristics of canine coronary resistance arteries：importance of endothelium[J].Am J Physiol，1989，257（2）：603-610.
[14]	Parikh KH，Chag MC，Shah KJ，et al.Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty：a clinical scenario of ischemic preconditioning[J].Can J Physiol Pharmacol，2007，85（3-4）：476-482.
[15]	许浩军，于宗良，顾明，等.经改制球囊导管冠脉内注射维拉帕米治疗无复流及慢血流的临床研究[J].中国循证心血管医学杂志，2015，7（4）：495-497.
[16]	Li JJ，Wu YJ，Qin XW.Should slow coronary flow be considered as a coronary syndrome?[J].Med Hypotheses，2006，66（5）：953-956.
[17]	Colhoun HM，Betteridge DJ，Durrington PN，et al.Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study（CARDS）：multicentre randomised placebo-controlled trial[J].Lancet，2004，364（9435）：685-696.
[18]	Yoshida H，Shoda T，Yanai H，et al.Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia[J].Atherosclerosis，2013，226（1）：161-164.
[19]	Caliskan M，Erdogan D，Gullu H，et al.Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow[J].Clin Cardiol，2007，30（9）：475-479.
[20]	Baykan AO，Kalkan GY，Sahin DY，et al.Coronary flow velocity reserve in donor artery and myocardial performance index after successful recanalization of chronic total coronary occlusions[J].J Invasive Cardiol，2015，27（6）：75-81.
[21]	Cakmak M，Tanriverdi H，Cakmak N，et al.Simvastatin may improve myocardial perfusion abnormality in slow coronary flow[J].Cardiology，2008，110（1）：39-44.
[22]	Jiang Q，Wu F，Wu Z，et al.Aspirin as a promising drug for slow coronary flow[J].Med Hypotheses，2012，79（5）：701-702.
[23]	Enli Y，Turk M，Akbay R，et al.Oxidative stress parameters in patients with slow coronary flow[J].Adv Ther，2008，25（1）：37-44.
[24]	Gokce M，Kaplan S，Tekelioglu Y，et al.Platelet function disorder in patients with coronary slow flow[J].Clin Cardiol，2005，28（3）：145-148.
[25]	Choi KN，Jin HY，Shin HC，et al.Comparison of the antiplatelet effects of once and twice daily low-dose ticagrelor and clopidogrel after percutaneous coronary intervention[J].Am J Cardiol，2017，120（2）：201-206.
[26]	Wang Y，Liu B，Chen L，et al.Safety and efficacy of lowdose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention[J].Platelets，2022，33（2）：304-311.
[27]	吴依霖，黄伟.曲美他嗪联合运动康复治疗老年慢性心力衰竭的疗效分析[J].重庆医学，2016，45（32）：4554-4558.
[28]	储毓舜，李东霞，张梅，等.外周血管疾病患者应用盐酸曲美他嗪治疗的效果评价[J].实用医学杂志，2016，32（24）：4097-4100.
[29]	张娟，薛一涛.冠状动脉微循环障碍中医治疗研究进展[J].辽宁中医药大学学报，2021，23（4）：153-156.
[30]	Daxin C，Shan L，Wen X，et al.Qualitative and quantitative analysis of the major constituents in Shexiang Tongxin Dropping Pill by HPLC-Q-TOF-MS/MS and UPLC-QqQMS/MS[J].Molecules，2015，20（10）：18597-18619.
[31]	Wang SH，Chu L，Xu Z，et al.Effect of Shexiang Tongxin Dropping Pills on the immediate blood flow of patients with coronary slow flow[J].Chin J Integr Med，2019，25（5）：360-365.
[32]	程晓昱，葛岚，张秀环.灯盏生脉胶囊对冠心病患者血脂水平的影响[J].广东医学，2010，31（15）：2030-2031.
[33]	宋艳，张红梅，马建建.灯盏花乙素苷元对大鼠血栓形成和血液流变学的影响[J].中国新药杂志，2011，20（15）：1446-1449.
[34]	柳岩，李远，肖文良，等.灯盏生脉对冠状动脉慢血流患者的临床疗效[J].广东医学，2017，38（4）：626-629.
[35]	雷玉华，唐其柱.灯盏生脉胶囊治疗冠心病心绞痛的Meta 分析[J].中国医学前沿杂志（电子版），2015，7（4）：45-49.
[36]	李斌.通络宁心方对冠状动脉慢血流患者冠脉血流速度及炎性因子的影响观察[J].中国民族民间医药，2018，27（15）：82-84.
[37]	Hadanny A，Rittblat M，Bitterman M，et al.Hyperbaric oxygen therapy improves neurocognitive functions of poststroke patients-a retrospective analysis[J].Restor Neurol Neurosci，2020，38（1）：93-107.
[38]	Li Y，Zhang H，Hao YF，et al.Evaluation of hyperbaric oxygen effects on slow coronary flow patients using gated myocardial perfusion imaging tomography[J].Undersea Hyperb Med，2018，45（4）：403-409.
[39]	De Ferrari GM，Schwartz PJ.Vagus nerve stimulation：from pre-clinical to clinical application：Challenges and future directions[J].Heart Fail Rev，2011，16（2）：195-203.
[40]	Stavrakis S，Humphrey MB，Scherlag BJ，et al.Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation[J].J Am Coll Cardiol，2015，65（9）：867-875.
[41]	Wang Z，Yu L，Huang B，et al.Low-level transcutaneous electrical stimulation of the auricular branch of vagus nerve ameliorates left ventricular remodeling and dysfunction by downregulation of matrix metalloproteinase 9 and transforming growth factor beta1[J].J Cardiovasc Pharmacol，2015，65（4）：342-348.